Clinical Trial Update: Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid [Phase 1]

View source ↗

Summary

A completed Phase 1 trial assessing AstraZeneca's PET imaging ligands [18F]AZD4694 and [11C]AZD2184 for detecting beta-amyloid in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [11C]AZD2184 (AZD2184)
• [18F]AZD4694 (AZD4694)

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED